HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vedin, I. Articles by Palmblad, J. Search for Related Content PubMed PubMed Citation Articles by Vedin, I. Articles by Palmblad, J. Agricola Articles by Vedin, I. Articles by Palmblad, J.

Effects of docosahexaenoic acid–rich n–3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study^1,2,3

¹ From the Department of Medicine (IV, JP) and the Department of Neurobiology, Caring Sciences and Society (YFL, AG, GFI, MEJ, and L-OW), Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden, and the Department of Public Health and Caring Sciences (TC, HB, and BV) Division of Geriatrics (HB) and the Division of Clinical Nutrition and Metabolism Research (TC and BV), Uppsala University Hospital, Uppsala, Sweden

Background:Dietary fish or fish oil rich in n–3 fatty acids (n–3 FAs), eg, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), ameliorate inflammatory reactions by various mechanisms. Whereas most studies have explored the effects of predominantly EPA-based n–3 FAs preparations, few have addressed the effects of n–3 FAs preparations with DHA as the main FA.

Objective:The objective was to determine the effects of 6 mo of dietary supplementation with an n–3 FAs preparation rich in DHA on release of cytokines and growth factors from peripheral blood mononuclear cells (PBMCs).

Design:In a randomized, double-blind, placebo-controlled trial, 174 Alzheimer disease (AD) patients received daily either 1.7 g DHA and 0.6 g EPA (n–3 FAs group) or placebo for 6 mo. In the present study blood samples were obtained from the 23 first randomized patients, and PBMCs were isolated before and after 6 mo of treatment.

Results:Plasma concentrations of DHA and EPA were significantly increased at 6 mo in the n–3 FAs group. This group also showed significant decreases of interleukin (IL)-6, IL-1β, and granulocyte colony-stimulating factor secretion after stimulation of PBMCs with lipopolysaccharide. Changes in the DHA and EPA concentrations were negatively associated with changes in IL-1β and IL-6 release for all subjects. Reductions of IL-1β and IL-6 were also significantly correlated with each other. In contrast, this n–3 FA treatment for 6 mo did not decrease tumor necrosis factor-, IL-8, IL-10, and granulocyte-macrophage colony-stimulating factor secretion.

Conclusion:AD patients treated with DHA-rich n–3 FAs supplementation increased their plasma concentrations of DHA (and EPA), which were associated with reduced release of IL-1β, IL-6, and granulocyte colony-stimulating factor from PBMCs. This trial was registered at clinicaltrials.gov as NCT00211159.